PEG-irinotecan is under clinical development by JenKem Technology and currently in Phase II for Glioblastoma Multiforme (GBM). According to GlobalData, Phase II drugs for Glioblastoma Multiforme (GBM) have a 23% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how PEG-irinotecan’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

PEG-irinotecan overview

PEG-Irinotecan is under development for the treatment of small cell lung cancer, relapsed or refractory cancers such as breast cancer, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, ovarian cancer and glioblastoma multiforme. Irinotecan targets topoisomerase I enzyme. The pegylated form enhances the permeability factor, tissue targeting property and enables prolonged action due to the polymeric nature. It is administered through parenteral and intravenous route.

JenKem Technology overview

JenKem Technology operates in pharmaceutical and healthcare industry. It is headquartered in China.

For a complete picture of PEG-irinotecan’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 7 February 2024

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.